• Globe Newswire

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development

Globenewswire -

• Globe Newswire

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Globenewswire -

• Globe Newswire

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

• Globe Newswire

Nemysis Limited Announces Successful IHAT-Gut Trial

DUBLIN, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Nemysis is pleased to announce the publication of the successful findings from the IHAT-Gut trial in...